WntResearch has included the first patient in the redesign of the proof of concept study NeoFox with the drug candidate Foxy-5
WntResearch announced today that the first patient has been included in the redesign of the Phase 2 clinical trial NeoFox, which is a proof of concept study with the drug candidate Foxy-5. The first patient was recruited at a trial center in Barcelona, Spain.The Phase 2 clinical trial NeoFox is a proof of concept study in patients with colon cancer which was originally intended to include a two year follow-up period of the patients. Positive ad hoc observations generated in the study enabled the design to be adjusted, which provides great benefits in terms of time and cost savings. The new